Cargando…
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma
Autores principales: | Sgherza, Nicola, Curci, Paola, Rizzi, Rita, Attolico, Immacolata, Loconsole, Daniela, Mestice, Anna, Chironna, Maria, Musto, Pellegrino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669415/ https://www.ncbi.nlm.nih.gov/pubmed/34907155 http://dx.doi.org/10.1038/s41408-021-00597-y |
Ejemplares similares
-
Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021) -
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021) -
Humoral Immune Response after anti-SARS-CoV-2 Vaccine “Booster” Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)
por: Sgherza, Nicola, et al.
Publicado: (2023) -
P-159: Effectiveness of anti-SARS-CoV-2 vaccine “booster” dose in patients with multiple myeloma
por: Sgherza, Nicola, et al.
Publicado: (2022) -
What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)